Response From Athersys on New Stroke Thrombectomy Treatment
Dec 30, 2018 21:26:25 GMT
avtech and jckrdu like this
Post by condo3e on Dec 30, 2018 21:26:25 GMT
Hospitals Rush to Offer New Stroke Treatment
Jacques Hayes, a Detroit-area construction worker, recently fell in his apartment. A visitor heard the thud in the next room, then saw Mr. Hayes struggle to walk and talk, falling a second time.
So the friend called 911.
Mr. Hayes was fortunate to be taken to Detroit’s Henry Ford Hospital, which is among a quickly growing number of U.S. hospitals offering a revolutionary stroke procedure known as a thrombectomy, in which a blood clot is quickly removed before a patient suffers lasting damage or death.
Hospitals are rushing to offer the procedure after groundbreaking new research has concluded the sooner the thrombectomy, the better the chances a severe stroke patient will recover, avoid disability, and in many cases recuperate enough to live independently.
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
Got this response from Athersys IR in response to my inquiry on the recent news on the expanded stroke thrombectomy treatment window. I am sure all are interested in this...
"This research is clearly a positive for stroke patients and a step in the right direction. It's also an important validation of something we have been saying for some time - in contrast to the conventional dogma, all the brain cells in the region of the ischemic event do not die in the immediate aftermath of the stroke, as people have long believed. These results are, in fact, consistent with ours in showing that the treatment window extends beyond the first several hours.
We do not feel these new guidelines will meaningfully affect our stroke program. As we have described previously, these two approaches could be quite complementary to one another, since thrombectomy allows for reperfusion, but does nothing to ameliorate the hyperinflammatory response from the spleen - whereas MultiStem can address this and provide benefits in other ways as well. MultiStem can be administered in addition to other treatments and layer right on top of the standard of care. However, in contrast to thrombectomy, treatment with MultiStem is also relevant to a much broader group of patients, for a meaningfully longer period of time, and the procedure is much simpler to perform.
Also, it is important to note that thrombectomy is only relevant to certain patients, and even with the extended window, there will be many patients where it's not an option or relevant. Furthermore, there is extensive clinical research that shows that the longer time frame after the stroke has occurred that reperfusion is achieved, the greater the risk of bleeding in the brain. This is because the artery walls can become structurally very weak when there is no blood flow or oxygen for an extended period of time. When blood flow is restored, the weakened artery wall is at risk of breaking or bursting open, causing brain hemorrhage - a real risk that could make things much worse. Again, this is why this approach will have to be used selectively.
We do not feel the new guidelines will have a meaningful effect on the MASTERS-2 trial. We also believe the advanced brain imaging technology is complimentary to MultiStem treatment, since they can be used together to help promote and monitor recovery for stroke patients."
Jacques Hayes, a Detroit-area construction worker, recently fell in his apartment. A visitor heard the thud in the next room, then saw Mr. Hayes struggle to walk and talk, falling a second time.
So the friend called 911.
Mr. Hayes was fortunate to be taken to Detroit’s Henry Ford Hospital, which is among a quickly growing number of U.S. hospitals offering a revolutionary stroke procedure known as a thrombectomy, in which a blood clot is quickly removed before a patient suffers lasting damage or death.
Hospitals are rushing to offer the procedure after groundbreaking new research has concluded the sooner the thrombectomy, the better the chances a severe stroke patient will recover, avoid disability, and in many cases recuperate enough to live independently.
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
Got this response from Athersys IR in response to my inquiry on the recent news on the expanded stroke thrombectomy treatment window. I am sure all are interested in this...
"This research is clearly a positive for stroke patients and a step in the right direction. It's also an important validation of something we have been saying for some time - in contrast to the conventional dogma, all the brain cells in the region of the ischemic event do not die in the immediate aftermath of the stroke, as people have long believed. These results are, in fact, consistent with ours in showing that the treatment window extends beyond the first several hours.
We do not feel these new guidelines will meaningfully affect our stroke program. As we have described previously, these two approaches could be quite complementary to one another, since thrombectomy allows for reperfusion, but does nothing to ameliorate the hyperinflammatory response from the spleen - whereas MultiStem can address this and provide benefits in other ways as well. MultiStem can be administered in addition to other treatments and layer right on top of the standard of care. However, in contrast to thrombectomy, treatment with MultiStem is also relevant to a much broader group of patients, for a meaningfully longer period of time, and the procedure is much simpler to perform.
Also, it is important to note that thrombectomy is only relevant to certain patients, and even with the extended window, there will be many patients where it's not an option or relevant. Furthermore, there is extensive clinical research that shows that the longer time frame after the stroke has occurred that reperfusion is achieved, the greater the risk of bleeding in the brain. This is because the artery walls can become structurally very weak when there is no blood flow or oxygen for an extended period of time. When blood flow is restored, the weakened artery wall is at risk of breaking or bursting open, causing brain hemorrhage - a real risk that could make things much worse. Again, this is why this approach will have to be used selectively.
We do not feel the new guidelines will have a meaningful effect on the MASTERS-2 trial. We also believe the advanced brain imaging technology is complimentary to MultiStem treatment, since they can be used together to help promote and monitor recovery for stroke patients."